HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators.

Abstract
The purpose of this study was to clarify the additive efficacy of short-acting β(2)-agonists (SABA) or muscarinic antagonists (SAMA) on dynamic hyperinflation and exercise tolerance in patients with chronic obstructive pulmonary disease (COPD) who had been treated with long-acting bronchodilators. Thirty-two patients with stable COPD who had been treated with long-acting bronchodilators, including long-acting muscarinic antagonists (LAMA), were examined by pulmonary function tests, dynamic hyperinflation evaluated by the method of step-wise metronome-paced incremental hyperventilation, and the incremental shuttle walking test before and after inhalation of SABA or SAMA. The additive efficacy of the two drugs was analyzed. Inhalation of SABA and SAMA improved airflow limitation and dynamic hyperinflation in stable COPD patients who had been treated with LAMA. Inhalation of SABA decreased respiratory resistance and the difference in respiratory resistance at 5 Hz and 20 Hz. On the whole, the additive efficacy of SABA on airflow limitation and dynamic hyperinflation was superior to that of SAMA. Furthermore, inhalation of SABA resulted in relief of breathlessness during exercise and significant improvement in exercise capacity. Inhalation of SABA resulted in significant improvement in exercise tolerance, which may have been due to improvement in dynamic hyperinflation. Single use of SABA before exercise, in addition to regular treatment with LAMA, may therefore be useful in stable COPD patients.
AuthorsYoshiaki Kitaguchi, Keisaku Fujimoto, Yoshimichi Komatsu, Masayuki Hanaoka, Takayuki Honda, Keishi Kubo
JournalRespiratory medicine (Respir Med) Vol. 107 Issue 3 Pg. 394-400 (Mar 2013) ISSN: 1532-3064 [Electronic] England
PMID23245993 (Publication Type: Journal Article, Randomized Controlled Trial)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents
  • Muscarinic Antagonists
  • Scopolamine Derivatives
  • Tiotropium Bromide
Topics
  • Administration, Inhalation
  • Adrenergic beta-2 Receptor Agonists (administration & dosage, therapeutic use)
  • Aged
  • Airway Resistance (drug effects)
  • Bronchodilator Agents (administration & dosage, therapeutic use)
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Exercise Test (methods)
  • Exercise Tolerance (drug effects)
  • Female
  • Forced Expiratory Volume (drug effects)
  • Humans
  • Male
  • Muscarinic Antagonists (administration & dosage, therapeutic use)
  • Pulmonary Disease, Chronic Obstructive (drug therapy, physiopathology)
  • Respiratory Rate (drug effects)
  • Scopolamine Derivatives (administration & dosage, therapeutic use)
  • Tiotropium Bromide

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: